ANVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

ANVS ▲ +42.14% at T+20d

NEUTRAL call ✓ call won +42.14% · α vs SPY +33.61% · entry $1.59 → $2.26

Next anchor: T+60d in 27d

Last close $1.79 (close Jun 8) · +12.58% from $1.59 entry

Entry anchored
Apr 9, 03:59 PM ET
via Databento tick

T+1d

+4.40%

call +4.40% · α +3.43%

$1.66

settled 8w ago

T+5d

+17.61%

call +17.61% · α +13.11%

$1.87

settled 8w ago

T+20d

+42.14%

call +42.14% · α +33.61%

$2.26

settled 5w ago

T+60d

—

call — · α —

—

in 27d

Price Chart

Loading chart...

Executive Summary

Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.

Actionable Insight

The stock may react negatively to the EPS miss and dilution, but the financing secures funding through the pivotal 2027 data readout, reducing near-term liquidity risk — monitor enrollment progress and upcoming trial updates.

Key Facts

Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
No revenue reported for the period
Closed $10M underwritten public offering, extending cash runway to Q2 2027
Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027
FDA to accept integrated safety data from both AD and PD trials for NDA submission
Parkinson's open-label study 28% enrolled since February 2026

Financial Impact

Dilutive offering of $10M at a loss-making stage; EPS miss of 8.3% but cash secured for key milestones

epscash runwaydilution

Risk Factors

Dilution from $10M public offering
No revenue and continued losses; dependence on trial outcomes
Clinical trial delays or negative data could derail NDA timeline

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3271713

7 reports for ANVS

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +11.63%May 20, 2026

Filters

Reports for ANVS — sortable, filterable
	Type				Now
May 20, 2026 20d ago	424B5 BEARISH ★ 6/10	$2.15 $1.90	▲ +11.63%	▲ +13.23%	$1.79 (+16.74%)
May 19, 2026 21d ago	424B5 BEARISH ★ 7/10	$2.04 $2.01	▲ +1.47%	▲ +2.71%	$1.79 (+12.25%)
May 15, 2026 25d ago	8-K MIXED ★ 5/10	$2.05 $2.06	▲ +0.49%	▼ −1.13%	$1.79 (−12.68%)
May 15, 2026 25d ago	Press Release BEARISH ★ 6/10	$2.06 $2.23	▼ −8.25%	▼ −7.29%	$1.79 (+13.11%)
Apr 10, 2026 8w ago	Press Release MIXED ★ 6/10	$1.59 $1.87	▲ +17.61%	▲ +13.11%	$1.79 (+12.58%)
Mar 19, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.15	▼ −19.48%	▼ −17.26%	$1.79 (−32.96%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.83 $2.50	▼ −11.66%	▼ −9.62%	$1.79 (−36.75%)

US Market Status

Market Closed — Opens in 7h 22m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access